An immunosuppressive tumor microenvironment is a major challenge for existing immunotherapies. A novel form of immunotherapy, known as peptide alarm therapy, has shown promise in activating the immune system within tumors by injecting viral peptides.
The newly approved Lifileucel stimulates tumor-infiltrating lymphocytes (TILs) unspecifically. Researchers are now investigating the degree to which neoantigens contribute to tumor regression under TIL therapy.
Over 90 percent of adults worldwide are infected with the Epstein-Barr virus (EBV). The virus belongs to the herpes viruses and stays in the body for a lifetime.